Please login to the form below

Not currently logged in
Email:
Password:

Renvela

This page shows the latest Renvela news and features for those working in and with pharma, biotech and healthcare.

Sanofi warns of difficult few months as diabetes sales slump

Sanofi warns of difficult few months as diabetes sales slump

The loss of patent protection for kidney disease drug Renvela/Renagel (sevelamer) also took its toll, according to chief executive Olivier Brandicourt, the architect of the turnaround plan at Sanofi, who

Latest news

  • Generic competition for Sanofi's Renvela hits UK market Generic competition for Sanofi's Renvela hits UK market

    Renvela is a next-generation version of Renagel (sevelamer hydrochloride) and combined global sales for the two medicines reached $861m at their peak in 2012. ... That was the exception however as most of the drugs, as with Renvela, saw primary care

  • Genzyme wins Scottish approval for Renvela

    Genzyme UK can supply Renvela within NHS Scotland after securing Scottish Medicine Consortium approval. ... Renvela is a medication for the control of serum phosphorous in patients with CKD.

  • PM Society Advertising Awards 2010

    Digital Media. Renvela by Langland on behalf of Genzyme. Digital Pioneer. Gary Monk  . GP Campaign. Apidra by Euro RSCG Life on behalf of sanofi-aventis   . Hospital Campaign.

  • Trials and tribulations

    Sevelamer carbonate. Renvela (Genzyme Corporation). Hypophosphataemia. US. Hydrocodone/ibuprofen. Ibudone (ProEthic Pharmaceuticals).

  • News in brief, May 02, 2007

    The Waterford site will also produce Genzyme's future products, including Tolevamer (GT160-246), a non-antibiotic toxin-binding polymer for the treatment of Clostridium difficile-associated diarrhoea (CDAD) and Renvela,

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics